Increasing Access to Lung Cancer Screening Act
The Increasing Access to Lung Cancer Screening Act would amend the Social Security Act to require Medicaid state plans to cover annual lung cancer screening, without cost sharing, for individuals whose screening is recommended under U.S. Preventive Services Task Force guidelines. It also extends Medicaid coverage for counseling and pharmacotherapy for tobacco cessation to all Medicaid beneficiaries, rather than limiting that benefit to pregnant women, and specifies that these services must be available without prior authorization. The bill further requires Medicaid managed care organizations to provide these benefits as part of their contracts.
In addition to Medicaid changes, the bill would prohibit prior authorization for annual lung cancer screening under Medicare, Medicare Advantage, and private group and individual health insurance coverage when screening is recommended by the relevant guidelines. It also directs the Department of Health and Human Services to run an education and outreach campaign on the importance of lung cancer screening, targeted to high-risk populations, and authorizes $10 million annually for fiscal years 2028 through 2032. Finally, it requires a GAO report on lung cancer demographics and screening gaps, including populations that may be missed by current eligibility criteria.
The bill’s impact would be to expand preventive lung cancer screening access across major coverage systems and reduce administrative barriers such as prior authorization and cost sharing. For Medicaid, it would create new mandatory coverage requirements for states and managed care plans, with a delayed effective date of January 1, 2028, and a transition period for states that need legislation to comply. For Medicare and private insurance, it would impose federal coverage rules that limit utilization management for qualifying screenings.
Overall sentiment appears supportive and public-health oriented, with the bill framed as an access and early-detection measure aimed at reducing lung cancer mortality and improving tobacco cessation services. No committee transcript or vote record is available in the provided material, so there is no recorded opposition or amendment debate to assess. The main points of potential contention are likely to be the new federal coverage mandates for states and insurers, the elimination of prior authorization, and the associated implementation and cost implications for Medicaid programs, Medicare plans, and private insurers.
The bill would amend multiple provisions of the Social Security Act and the Public Health Service Act to make lung cancer screening and tobacco cessation services more broadly available and less restricted by prior authorization or cost sharing. It would require Medicaid coverage of annual lung cancer screening and expand Medicaid tobacco-cessation benefits to all enrollees, while also binding Medicaid managed care organizations to cover those services. It would also add federal prohibitions on prior authorization for qualifying lung cancer screening in Medicare, Medicare Advantage, and private health plans, and would require HHS outreach plus a GAO study on screening gaps.
The bill’s apparent sentiment is strongly favorable, centered on preventive care, early detection, and smoking cessation. The text reflects a health-access approach rather than a partisan or procedural controversy, and the available context shows only introduction and referral with no recorded votes or committee debate. Because no transcript or vote history is provided, there is no evidence of formal opposition in the record supplied.
The most likely points of contention are the federal mandates imposed on state Medicaid programs and private insurers, especially the requirement to cover screening without cost sharing and without prior authorization. States may be concerned about implementation costs, administrative changes, and the need for state legislation before compliance. Insurers and managed care organizations may object to limits on utilization management tools. Another possible area of debate is the bill’s reliance on USPSTF and Secretary-issued screening guidelines, which could affect eligibility and coverage scope.